MDGL — Madrigal Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $7.22bn
- $6.41bn
- $180.13m
- 63
- 7
- 100
- 57
Annual cashflow statement for Madrigal Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -202 | -242 | -295 | -374 | -466 |
| Depreciation | |||||
| Non-Cash Items | 20.7 | 26.9 | 32.4 | 52.1 | 81.6 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 23.5 | 30.7 | 37.6 | -3.28 | -72.3 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -158 | -184 | -225 | -324 | -456 |
| Capital Expenditures | -0.334 | -0.209 | -0.217 | -1.48 | -6.46 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 160 | -4.85 | 207 | -501 | -268 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 160 | -5.05 | 207 | -503 | -274 |
| Financing Cash Flow Items | — | — | -0.886 | -0.363 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 5.09 | 171 | 313 | 595 | 735 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 7.31 | -17.7 | 295 | -232 | 5.1 |